Sichuan Kelun Pharmaceutical (002422.SZ): Bevacizumab Monoclonal Antibody for the Treatment of 2L+ HER2+ Breast Cancer Approved for Market Launch
Kelon Pharmaceutical (002422.SZ) announced that its holding subsidiary Sichuan Kelon Botai Biopharmaceutical Co., Ltd...
Sichuan Kelun Pharmaceutical (002422.SZ) announced that its controlling subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd. (referred to as "Kelun Botai"), has obtained approval from the National Medical Products Administration (NMPA) for the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (also known as A166) (Shutailai) targeting human epidermal growth factor receptor 2 (HER2). This medication is approved for use in unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.
Related Articles
US Stock Market Move | ACCL.US, a company controlled by Zhuo Yuan, has landed on the US stock market with a 1.75% increase in trading at the opening.
US Stock Market Move | NVIDIA Corporation holds Concept Stock Coreweave (CRWV.US), which fell more than 7%.
US Stock Market Move | Reach a $1.085 billion cooperation agreement with domestic and foreign pharmaceutical companies, Rani Therapeutics (RANI.US) soars over 265%.
US Stock Market Move | ACCL.US, a company controlled by Zhuo Yuan, has landed on the US stock market with a 1.75% increase in trading at the opening.
US Stock Market Move | NVIDIA Corporation holds Concept Stock Coreweave (CRWV.US), which fell more than 7%.
US Stock Market Move | Reach a $1.085 billion cooperation agreement with domestic and foreign pharmaceutical companies, Rani Therapeutics (RANI.US) soars over 265%.
RECOMMEND
